Cardiovascular Disease: ASCVD Pathogenesis, Lipid Biology, and Evidence-Based Risk Management
Dr. Joshua Lindsley, DO|Last Updated: March 2026|22 min read
Key Takeaways
ASCVD is fundamentally caused by apoB-containing lipoproteins delivering cholesterol to artery walls — not simply "high cholesterol"
apoB directly measures atherogenic particle number and correlates more strongly with disease outcomes than LDL-C, especially in patients with insulin resistance
Lp(a) affects ~20% of the population, is 90% genetically determined, and confers ~6× greater risk per particle than LDL yet remains undertested
Brain cholesterol is synthesized locally and independent of circulating levels, making concerns about statins causing dementia unsupported by evidence
Treatment should target apoB levels appropriate to individual risk (≤60-80 mg/dL for high-risk patients) using evidence-based therapies
Summary
This educational brief provides a comprehensive examination of atherosclerotic cardiovascular disease (ASCVD) from first principles, covering the biological mechanisms of disease development, the crucial distinction between risk factors and risk markers, and evidence-based approaches to prevention and treatment.
A central insight is that ASCVD is fundamentally a disease of apoB-containing lipoproteins delivering cholesterol to the artery wall—not simply "high cholesterol." This distinction has profound implications for both measurement and treatment. The standard lipid panel measuring LDL-cholesterol (LDL-C) captures only one dimension of risk; apoB directly measures the number of atherogenic particles, which correlates more strongly with disease outcomes.
The discussion of Lp(a) reveals a genetically determined risk factor affecting approximately 20% of the population that remains undertested and undertreated. Unlike LDL, Lp(a) levels are 90% genetically determined and largely unresponsive to lifestyle modification. New therapies specifically targeting Lp(a) are in development and represent a significant advancement in cardiovascular prevention.
The relationship between insulin resistance and cardiovascular risk operates through lipoprotein metabolism—hyperinsulinemia promotes a distinctive pattern of small, dense LDL particles, elevated triglycerides, and low HDL that dramatically increases atherogenic potential even when LDL-C appears normal.
ASCVD: Definition and Pathogenesis
What ASCVD Actually Is
Concept
Definition
Atherosclerosis
Deposition of cholesterol in the walls of arteries
ASCVD
Clinical consequences of atherosclerosis (heart attack, stroke, peripheral artery disease)
Fundamental cause
apoB-containing lipoproteins delivering cholesterol to subendothelial space
Time course
Decades-long silent development before clinical events
The Bottom Line
Atherosclerotic cardiovascular disease is fundamentally caused by apoB-containing lipoproteins delivering cholesterol to artery walls over decades—a process that begins in adolescence and progresses silently until catastrophic events occur.2 The standard LDL-cholesterol measurement systematically underestimates risk in patients with insulin resistance, metabolic syndrome, or other conditions producing small, dense LDL particles; apoB directly measures atherogenic particle number and should be included in risk assessment.1 Lipoprotein(a) affects approximately 20% of the population, is 90% genetically determined, responds minimally to lifestyle modification, and confers approximately 6× greater atherogenic risk per particle than equivalent LDL—yet remains undertested.3 Brain cholesterol is synthesized locally and independent of circulating levels, making concerns about statins causing dementia unsupported by evidence. Treatment should target apoB levels appropriate to individual risk (≤60-80 mg/dL for high-risk patients), using lifestyle modification as a foundation with pharmacotherapy—statins, ezetimibe, PCSK9 inhibitors—added as needed to achieve targets.
Continue Reading This Evidence-Based Guide
Free access to 235+ health education guides from Highland Longevity
No spam. Unsubscribe anytime.
Risk Factors vs Risk Markers
Critical Distinction
Category
Definition
Examples
Intervention Impact
Causal risk factor
Directly participates in disease process
apoB, blood pressure, smoking
Reducing factor reduces disease
Risk marker
Correlates with disease but not causal
CRP, homocysteine
Reducing marker may not reduce disease
Causal Risk Factors for ASCVD
Factor
Mechanism
Modifiability
apoB-containing lipoproteins
Deliver cholesterol to artery wall
Highly modifiable
Hypertension
Endothelial damage, promotes particle penetration
Highly modifiable
Smoking
Endothelial dysfunction, oxidative stress
Completely modifiable
Diabetes/insulin resistance
Lipoprotein abnormalities, inflammation
Modifiable
Age
Cumulative exposure, reduced repair
Not modifiable
Why apoB Is Superior to LDL-C
Measurement
What It Captures
Limitation
LDL-C
Cholesterol mass in LDL particles
Doesn't account for particle number or size
LDL-P
Number of LDL particles
Requires specialized testing
apoB
Number of all atherogenic particles
One apoB molecule per particle; directly measurable
The standard lipid panel would classify these patients as equivalent risk. apoB measurement reveals the true difference.
NLA Consensus Statement on apoB1
Recommendation
Rationale
apoB should be measured in all patients
More accurate risk assessment than LDL-C
Particularly important in metabolic syndrome
LDL-C often normal despite high particle number
Treatment targets should include apoB
<90 mg/dL moderate risk; <80 mg/dL high risk; <60 mg/dL very high risk
Lp(a): The Forgotten Risk Factor
Structure and Biology
Feature
Description
Composition
LDL particle + apolipoprotein(a) attached
Inheritance
90% genetically determined
Prevalence of elevation
~20% of population
Atherogenicity
~6× more atherogenic than equivalent LDL per particle3
Thrombogenicity
Also promotes clot formation
Why Lp(a) Is So Dangerous
Property
Mechanism
Prolonged residence time
Cleared more slowly than LDL
Preferential retention
Binds more avidly to artery wall
Pro-inflammatory
Carries oxidized phospholipids
Pro-thrombotic
Structural similarity to plasminogen
Testing Recommendations
Aspect
Recommendation
Who to test
All adults at least once; family history of premature CVD
When to test
Once in lifetime (levels stable); not affected by fasting
Units
nmol/L preferred; mg/dL less standardized
Threshold for concern
>50 nmol/L (>30 mg/dL) indicates elevated risk
High-risk threshold
>125 nmol/L substantially elevated
Current and Future Treatments
Treatment
Effect on Lp(a)
Notes
Lifestyle
Minimal (<10% reduction)
Exercise, diet have little effect
Statins
May increase slightly
Paradoxical effect; still net beneficial
Niacin
20-30% reduction
Limited by side effects
PCSK9 inhibitors
20-30% reduction
Modest effect; primarily lowers LDL
Antisense oligonucleotides (in development)
80-90% reduction
Pelacarsen in Phase 3 trials
siRNA therapies (in development)
80-90% reduction
Emerging options
Key insight
Elevated Lp(a) is one of the most common genetic risk factors for cardiovascular disease, yet it remains undertested. Unlike LDL, Lp(a) cannot be meaningfully lowered with diet, exercise, or most current medications. Identifying elevated Lp(a) allows for more aggressive management of other modifiable risk factors.
The patient with metabolic syndrome and an LDL-C of 100 mg/dL may have the same atherogenic particle burden as someone with an LDL-C of 160 mg/dL. The standard lipid panel systematically underestimates risk in insulin-resistant patients.
Brain Cholesterol and Cognitive Function
Brain Cholesterol Independence
Principle
Explanation
Blood-brain barrier
Cholesterol cannot cross from blood to brain
Local synthesis
Brain makes all its own cholesterol
Critical function
Essential for synaptic function, myelination
apoE role
Primary cholesterol transport protein in brain
apoE Genotype and Brain Health
Genotype
Prevalence
Alzheimer's Risk
Cholesterol Implications
E2/E2
~1%
Lower
May have elevated triglycerides
E3/E3
~60%
Average
Reference population
E3/E4
~25%
3× increased
Affects brain cholesterol transport
E4/E4
~2-3%
12× increased
Significant impairment
Statins and Cognitive Function
Concern
Evidence
"Statins cause dementia"
Not supported by evidence
Mechanism consideration
Statins don't cross BBB significantly
Observational data
Statin users have lower dementia rates
Clinical trials
No cognitive impairment signal
Desmosterol as biomarker
Measures brain cholesterol synthesis separately
Key insight
The brain maintains its own cholesterol economy independent of circulating levels. Lowering blood cholesterol with statins does not deprive the brain of needed cholesterol. The association between "high cholesterol" and dementia is confounded by survival bias—healthier people with lower cardiovascular risk live long enough to develop dementia.
apoB measurement standardization: While increasingly available, apoB testing is not yet universally reimbursed by all insurers despite NLA recommendations.1
Mendelian randomization studies2: Genetic studies provide strong causal inference but cannot account for all environmental interactions or gene-environment effects.
Lp(a) atherogenicity estimates3: The ~6× atherogenicity figure comes from comparing per-particle risk; actual population risk contribution depends on absolute Lp(a) levels.
Conflicting Evidence
LDL-C vs apoB targets: While apoB is considered superior, most clinical trial evidence for cardiovascular outcomes was generated using LDL-C targets.
Statin cognitive effects: Some patients report cognitive symptoms on statins; randomized trials show no signal, but individual experiences may vary.
apoB treatment targets: Optimal apoB thresholds derived from consensus rather than dedicated randomized trials.
Combination therapy sequencing: Optimal order of adding therapies (statin → ezetimibe → PCSK9i vs other sequences) not formally tested.
Recent Developments
2024 NLA apoB Consensus1: First comprehensive expert consensus specifically addressing apoB measurement and clinical use.
Lp(a) drug development4: Multiple RNA-based therapies showing 80-90% Lp(a) reduction in Phase 2/3 trials.
JACC Lp(a) atherogenicity study3: 2024 Mendelian randomization study quantifying Lp(a)'s ~6× greater atherogenicity per particle versus LDL.
References
Ballantyne, C. M., Bays, H. E., Braun, L. T., et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology, 18(5), e647-e663. https://doi.org/10.1016/j.jacl.2024.08.007
Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
Björnson, E., Adiels, M., Taskinen, M. R., et al. (2024). Lipoprotein(a) is markedly more atherogenic than LDL: An apolipoprotein B-based genetic analysis. Journal of the American College of Cardiology, 83(3), 385-395. https://doi.org/10.1016/j.jacc.2023.10.039
Rider, D. A., Eisermann, M., Germann, K., et al. (2022). Lp(a)HORIZON: Design and rationale of a Phase 3 cardiovascular outcomes study evaluating pelacarsen in patients with established CVD and elevated Lp(a). American Heart Journal, 246, 1-11. https://doi.org/10.1016/j.ahj.2021.12.008
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of March 2026 and may be updated as new evidence becomes available.
Have Questions About Heart Health?
Dr. Lindsley can help you understand your cardiovascular risk and create an evidence-based prevention plan.